Tyrosine Protein Kinase JAK3 - Pipeline Review, H2 2020
Tyrosine Protein Kinase JAK3 - Pipeline Review, H2 2020
SUMMARY
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) pipeline Target constitutes close to 36 molecules. Out of which approximately 36 molecules are developed by Companies. The latest report Tyrosine Protein Kinase JAK3 - Pipeline Review, H2 2020, outlays comprehensive information on the Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 7, 2, 2, 16 and 3 respectively.
Report covers products from therapy areas Immunology, Dermatology, Gastrointestinal, Musculoskeletal Disorders, Oncology, Respiratory, Infectious Disease, Ophthalmology, Cardiovascular and Central Nervous System which include indications Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Inflammatory Bowel Disease, Psoriasis, Alopecia Areata, Ulcerative Colitis, Vitiligo, Asthma, Crohn's Disease (Regional Enteritis), Chronic Cutaneous Lupus Erythematosus (CCLE)/Discoid Lupus Erythematosus (DLE), Coronavirus Disease 2019 (COVID-19), Diffuse Large B-Cell Lymphoma, Inflammation, Systemic Lupus Erythematosus, Acute Lung Injury, Allergic Conjunctivitis, Anaplastic Large Cell Lymphoma (ALCL), Androgenic Alopecia, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, Autoimmune Disorders, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Cachexia, Celiac Disease, Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Cutaneous T-Cell Lymphoma, Dermatitis (Eczema), Dermatomyositis, Dermatosis, Fibrosis, Follicular Lymphoma, Graft Versus Host Disease (GVHD), Ischemia Reperfusion Injury, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Multiple Sclerosis, Myeloproliferative Disorders, Pemphigus Vulgaris, Peripheral T-Cell Lymphomas (PTCL), Pneumonia, Polyarticular Juvenile Idiopathic Arthritis (PJIA), Pruritus, Psoriatic Arthritis, Sarcoidosis, Sarcopenia, Systemic Sclerosis (Scleroderma) and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) pipeline Target constitutes close to 36 molecules. Out of which approximately 36 molecules are developed by Companies. The latest report Tyrosine Protein Kinase JAK3 - Pipeline Review, H2 2020, outlays comprehensive information on the Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 7, 2, 2, 16 and 3 respectively.
Report covers products from therapy areas Immunology, Dermatology, Gastrointestinal, Musculoskeletal Disorders, Oncology, Respiratory, Infectious Disease, Ophthalmology, Cardiovascular and Central Nervous System which include indications Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Inflammatory Bowel Disease, Psoriasis, Alopecia Areata, Ulcerative Colitis, Vitiligo, Asthma, Crohn's Disease (Regional Enteritis), Chronic Cutaneous Lupus Erythematosus (CCLE)/Discoid Lupus Erythematosus (DLE), Coronavirus Disease 2019 (COVID-19), Diffuse Large B-Cell Lymphoma, Inflammation, Systemic Lupus Erythematosus, Acute Lung Injury, Allergic Conjunctivitis, Anaplastic Large Cell Lymphoma (ALCL), Androgenic Alopecia, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, Autoimmune Disorders, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Cachexia, Celiac Disease, Chronic Obstructive Pulmonary Disease (COPD), Colorectal Cancer, Cutaneous T-Cell Lymphoma, Dermatitis (Eczema), Dermatomyositis, Dermatosis, Fibrosis, Follicular Lymphoma, Graft Versus Host Disease (GVHD), Ischemia Reperfusion Injury, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Multiple Sclerosis, Myeloproliferative Disorders, Pemphigus Vulgaris, Peripheral T-Cell Lymphomas (PTCL), Pneumonia, Polyarticular Juvenile Idiopathic Arthritis (PJIA), Pruritus, Psoriatic Arthritis, Sarcoidosis, Sarcopenia, Systemic Sclerosis (Scleroderma) and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Development
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Assessment
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Drug Profiles
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Product Development Milestones
Appendix
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Development
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Assessment
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Drug Profiles
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Aclaris Therapeutics Inc, H2 2020
Pipeline by Alexion Pharmaceuticals Inc, H2 2020
Pipeline by Arrien Pharmaceuticals LLC, H2 2020
Dormant Products, H2 2020
Discontinued Products, H2 2020
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Aclaris Therapeutics Inc, H2 2020
Pipeline by Alexion Pharmaceuticals Inc, H2 2020
Pipeline by Arrien Pharmaceuticals LLC, H2 2020
Dormant Products, H2 2020
Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
COMPANIES MENTIONED
Aclaris Therapeutics Inc
Alexion Pharmaceuticals Inc
Arrien Pharmaceuticals LLC
Astellas Pharma Inc
Bristol-Myers Squibb Co
Chipscreen Biosciences Ltd
Clevexel Pharma SAS
Daewoong Pharmaceutical Co Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
Impetis Biosciences Ltd
Japan Tobacco Inc
KBP BioSciences Co Ltd
Merck & Co Inc
MYOS RENS Technology Inc
Novartis AG
Oncostellae SL
Pfizer Inc
Sienna Biopharmaceuticals Inc
Simcere Pharmaceutical Group
Theravance Biopharma Inc
Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
COMPANIES MENTIONED
Aclaris Therapeutics Inc
Alexion Pharmaceuticals Inc
Arrien Pharmaceuticals LLC
Astellas Pharma Inc
Bristol-Myers Squibb Co
Chipscreen Biosciences Ltd
Clevexel Pharma SAS
Daewoong Pharmaceutical Co Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
Impetis Biosciences Ltd
Japan Tobacco Inc
KBP BioSciences Co Ltd
Merck & Co Inc
MYOS RENS Technology Inc
Novartis AG
Oncostellae SL
Pfizer Inc
Sienna Biopharmaceuticals Inc
Simcere Pharmaceutical Group
Theravance Biopharma Inc
